Telomir Pharmaceuticals, Inc.
TELO Nasdaq· Pharmaceutical Preparations
Last close · Oct 23, 2026
$0.98
KIRA · Stoqly’s AI analyst, in plain words
- Telomir Pharmaceuticals, Inc. lost $10.4M in fiscal 2025.
Market cap
$59.3M
P/E
—
Revenue
—
Net income
−$10.4M
Free cash flow
—
Operating margin
—
Telomir Pharmaceuticals, Inc. in 30 seconds · fiscal 2025
Does it make a profit?
−$10.4M
No. It lost money last year.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Telomir Pharmaceuticals, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 17, 2026
- Legal name
- Telomir Pharmaceuticals, Inc.
- CIK
- 0001971532
Telomir Pharmaceuticals, Inc. · TELO
Results and finances
The last 4 fiscal years. Amounts in USD.
| Fiscal year | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|
| Sales and profit | ||||
| Net income | −$0.9M | −$13.1M | −$16.5M | −$10.4M |
| Diluted EPS | −$0.03 | $0.48 | −$0.56 | −$0.33 |
| Cash | ||||
| Cash from operations | −$0.5M | −$3.9M | −$5.1M | −$3.7M |
| Share count change | — | 1.8% | 8.2% | 7.2% |
| Debt and strength | ||||
| Cash and short-term investments | $0.0M | $0.0M | $1.3M | $7.3M |
| Shareholders' equity | −$0.9M | $3.4M | $0.6M | $5.9M |
| Current ratio | 0.0x | 0.3x | 1.9x | 5.1x |
| Returns and quality | ||||
| Return on equity | — | −1,045.4% | −810.2% | −317.6% |
| Return on tangible equity | — | −380.2% | −2,571.2% | −176.1% |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Telomir Pharmaceuticals, Inc. · TELO
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $0.98 a share, the company is worth $59.3M.
Source: SEC EDGAR XBRL filings (CIK 0001971532). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.